Systematic review for the 2017 ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association Task Force on Clinical practice guidelines

Hypertension

Volumn 71, Issue 6, 2018, Pages E116-E135

  Reboussin, David M ^c   Allen, Norrina B ^c   Griswold, Michael E ^c   Guallar, Eliseo ^c   Hong, Yuling ^c   Lackland, Daniel T ^c   Miller, Edgar R ^c   Polonsky, Tamar ^c   Thompson Paul, Angela M ^c   Vupputuri, Suma ^c   Levine, Glenn N ^c   O'Gara, Patrick T ^c   Halperin, Jonathan L ^c   Past, Immediate ^c   Al Khatib, Sana M ^c   Beckman, Joshua A ^c   Birtcher, Kim K ^c   Bozkurt, Biykem ^c   Brindis, Ralph G ^c   Cigarroa, Joaquin E ^c   Curtis, Lesley H ^c   Deswal, Anita ^c   Fleisher, Lee A ^c   Gentile, Federico ^c   Gidding, Samuel ^c   Goldberger, Zachary D ^c   Hlatky, Mark A ^c   Ikonomidis, John ^c   Joglar, José A ^c   Mauri, Laura ^c   Pressler, Susan J ^c   Riegel, Barbara ^c   Wijeysundera, Duminda N ^c   Walsh, Mary Norine ^a   Jacobovitz, Shalom ^a   Oetgen, William J ^a   Elma, MaryAnne ^a   Scholtz, Amelia ^a   Sheehan, Katherine ^b   Abdullah, Abdul R ^b   Tahir, Naira ^b   Warner, John J ^b   Brown, Nancy ^b   Robertson, Rose Marie ^b   Whitman, Gayle R ^b   Hundley, Jody ^b   more..

^a Agriculture Policy Resources Science and Industry Division   (United States)

^b Office of Science Operations   (United States)

^c NONE

Author keywords

AHA Scientific Statements; Antihypertensive drug class; Blood pressure; Cardiovascular disease; Evidence Review Committee; Home blood pressure monitoring; Hypertension; Meta analysis; Risk reduction; Targets; Treatment outcomes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; AMBULATORY CARE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOLOGY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CLINICAL OUTCOME; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTENSIVE PATIENT; MAJOR ADVERSE CARDIAC EVENT; MEDICAL SOCIETY; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SELF EXAMINATION; SELF MONITORING; SYSTEMATIC REVIEW; BLOOD PRESSURE; PATHOPHYSIOLOGY; PHYSIOLOGY; UNITED STATES;

ADULT; AMERICAN HEART ASSOCIATION; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOLOGY; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 85060331053     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYP.0000000000000067     Document Type: Review

References (85)

1. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (US). Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011.
2. Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (US). Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: National Academies Press; 2011.
3. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association. 2010. Available at: http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ ucm_319826.pdf. Accessed September 15, 2017.
4. Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/ AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;133:1426-28.
5. Jacobs AK, Kushner FG, Ettinger SM, et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:268-310.
6. Jacobs AK, Anderson JL, Halperin JL. The evolution and future of ACC/ AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:1208-17.
7. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360.
8. Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008;52:10-29.
9. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219.
10. Fujiwara T, Nishimura T, Ohkuko T, et al. Rationale and design of HOMED-BP Study: hypertension objective treatment based on measurement by electrical devices of blood pressure study. Blood Press Monit. 2002;7:77-82.
11. Bliziotis IA, Destounis A, Stergiou GS. Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis. J Hypertens. 2012;30:1289-99.
12. Gaborieau V, Delarche N, Gosse P. Ambulatory blood pressure monitoring versus self-measurement of blood pressure at home: correlation with target organ damage. J Hypertens. 2008;26:1919-27.
13. Ward AM, Takahashi O, Stevens R, et al. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens. 2012;30:449-56.
14. Uhlig K, Patel K, Ip S, et al. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. Ann Intern Med. 2013;159:185-94.
15. Marquez-Contreras E, Martell-Claros N, Gil-Guillen V, et al. Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study. J Hypertens. 2006;24:169-75.
16. Staessen JA, Den Hond E, Celis H, et al. Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: a randomized controlled trial. JAMA. 2004;291:955-64.
17. Soghikian K, Casper SM, Fireman BH, et al. Home blood pressure monitoring. Effect on use of medical services and medical care costs. Med Care. 1992;30:855-65.
18. Bosworth HB, Olsen MK, Grubber JM, et al. Two self-management interventions to improve hypertension control: a randomized trial. Ann Intern Med. 2009;151:687-95.
19. McKinstry B, Hanley J, Wild S, et al. Telemonitoring based service redesign for the management of uncontrolled hypertension: multicentre randomised controlled trial. BMJ. 2013;346:f3030.
20. Midanik LT, Resnick B, Hurley LB, et al. Home blood pressure monitoring for mild hypertensives. Public Health Rep. 1991;106:85-9.
21. Godwin M, Lam M, Birtwhistle R, et al. A primary care pragmatic cluster randomized trial of the use of home blood pressure monitoring on blood pressure levels in hypertensive patients with above target blood pressure. Fam Pract. 2010;27:135-42.
22. Verberk WJ, Kroon AA, Lenders JWM, et al. Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. Hypertension. 2007;50:1019-25.
23. McManus RJ, Mant J, Roalfe A, et al. Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis. BMJ. 2005;331:493.
24. Varis J, Kantola I. The choice of home blood pressure result reporting method is essential: results mailed to physicians did not improve hypertension control compared with ordinary office-based blood pressure treatment. Blood Press. 2010;19:319-24.
25. Oliver S, Jones J, Leonard D, et al. Improving adherence with amlodip-ine/atorvastatin therapy: IMPACT study. J Clin Hypertens (Greenwich). 2011;13:598-604.
26. Hebert PL, Sisk JE, Tuzzio L, et al. Nurse-led disease management for hypertension control in a diverse urban community: a randomized trial. J Gen Intern Med. 2012;27:630-9.
27. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310:46-56.
28. Magid DJ, Olson KL, Billups SJ, et al. A pharmacist-led, American Heart Association Heart 360 Web-enabled home blood pressure monitoring program. Circ Cardiovasc Qual Outcomes. 2013;6:157-63.
29. Hosseininasab M, Jahangard-Rafsanjani Z, Mohagheghi A, et al. Self-monitoring of blood pressure for improving adherence to antihypertensive medicines and blood pressure control: a randomized controlled trial. Am J Hypertens. 2014;27:1339-45.
30. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
31. Higgins JPT, Altman DG,Gotzsche PC, et al.The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J (Clin Res Ed). 2011;343:d5928.
32. Centers for Disease Control and Prevention. Self-Measured Blood Pressure Monitoring: Action Steps for Clinicians. 2014. Centers for Disease Control and Prevention, US Dept of Health and Human Services: Atlanta, GA:3-10.
33. Xu W, Goldberg SI, Shubina M, et al. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ. 2015;350:h158.
34. GBD 2013 Risk Factors Collaborators; Forouzanfar MH, Alexander L, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:2287-323.
35. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011;377:568-77.
36. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-60.
37. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34:613-22.
38. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435-43.
39. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67.
40. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol. 2015;65:1998-2038.
41. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. London, UK: Royal College of Physicians (UK); 2011.
42. Lackland DT, Roccella EJ, Deutsch AF, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke. 2014;45:315-53.
43. Bangalore S, Toklu B, Gianos E, et al. Optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med. 2017;130:707-19.e8.
44. Bavishi C, Bangalore S, Messerli FH. Outcomes of intensive blood pressure lowering in older hypertensive patients. J Am Coll Cardiol. 2017;69:486-93.
45. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717.
46. Weiss J, Freeman M, Low A, et al. Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older: a systematic review and meta-analysis. Ann Intern Med. 2017;166:419-29.
47. Verdecchia P, Angeli F, Gentile G, et al. More versus less intensive blood pressure-lowering strategy: novelty and significance. Hypertension. 2016;68:642-53.
48. Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. SPS3 Study Group. Lancet. 2013;382:507-15.
49. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103-16.
50. Lv J, Neal B, Ehteshami P, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001293.
51. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J (Clin Res Ed). 2003;327:557-60.
52. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58.
53. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101.
54. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
55. Viechtbauer W. Conducting a meta-analysis in R with the metafor package. J Statistical Software. 2010;36.
56. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142:342-51.
57. Norris K, Bourgoigne J, Gassman J, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis. 2006;48:739-51.
58. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-31.
59. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for reno-protection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939-46.
60. Asayama K, Ohkubo T, Metoki H, et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertens Res. 2012;35:1102-10.
61. Schrier RW, Abebe KZ, Perrone RD, et al. Blood pressure in early auto-somal dominant polycystic kidney disease. N Engl J Med. 2014;371: 2255-66.
62. Verdecchia P, Staessen JA, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374:525-33.
63. Ismail-Beigi F, Craven TE, O'Connor PJ, et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int. 2012;81:586-94.
64. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. ACCORD Study Group. N Engl J Med. 2010;362:1575-85.
65. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-13.
66. Davis EM, Appel LJ, Wang X, et al. Limitations of analyses based on achieved blood pressure: lessons from the African American Study of Kidney Disease and Hypertension Trial. Hypertension. 2011;57:1061-68.
67. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31:2115-27.
68. Hayashi K, Saruta T, Goto Y, et al. Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res. 2010;33:1211-20.
69. Ogihara T, Saruta T, Matsuoka H, et al. Valsartan in elderly isolated systolic hypertension (VALISH) study: rationale and design. Hypertens Res. 2004;27:657-61.
70. Wei Y, Jin Z, Shen G, et al. Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years. J Clin Hypertens (Greenwich). 2013;15:420-7.
71. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62.
72. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, reti-nopathy and strokes. Kidney Int. 2002;61:1086-97.
73. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-20.
74. Wright JT Jr, Fine LJ, Lackland DT, et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014;160:499-503.
75. Chobanian AV. Guidelines for the management of hypertension. Med Clin North Am. 2017;101:219-27.
76. Kovell LC, Ahmed HM, Misra S, et al. US hypertension management guidelines: a review of the recent past and recommendations for the future. J Am Heart Assoc. 2015;4:e002315.
77. Qaseem A, Wilt TJ, Rich R, et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017;166:430-7.
78. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;136:e137-61.
79. Guilbert JJ. The world health report 2002-reducing risks, promoting healthy life. Educ Health (Abingdon). 2003;16:230.
80. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534-44.
81. Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607-17.
82. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
83. Chen N, Zhou M, Yang M, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev. 2010:Cd003654.
84. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-35.
85. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.